AR109467A1 - Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño - Google Patents
Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueñoInfo
- Publication number
- AR109467A1 AR109467A1 ARP170102402A ARP170102402A AR109467A1 AR 109467 A1 AR109467 A1 AR 109467A1 AR P170102402 A ARP170102402 A AR P170102402A AR P170102402 A ARP170102402 A AR P170102402A AR 109467 A1 AR109467 A1 AR 109467A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- corresponds
- procedure
- disorders
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Compuesto, caracterizado por presentar la fórmula general (1), donde X corresponde a un átomo de oxígeno o de azufre; A corresponde a un grupo alquilo lineal C₂₋₄, el cual puede tener uno o más de sus hidrógenos sustituido(s) por un grupo alquilo seleccionado de metilo, etilo, propilo o isopropilo; R¹ corresponde a un grupo alquilo C₁₋₆, o alquenilo C₂₋₆, o alquinilo C₂₋₆, o haloalquilo C₁₋₆, o cicloalquilo C₃₋₆, o alquilo C₁₋₂-cicloalquilo C₃₋₆; R² corresponde a un hidrógeno o un grupo alquilo C₁₋₃; R³ corresponde a un átomo de hidrógeno o de halógeno; R⁴ corresponde a un grupo alquilo C₁₋₆; n es 0 ó 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109467A1 true AR109467A1 (es) | 2018-12-12 |
Family
ID=62023150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102402A AR109467A1 (es) | 2016-10-24 | 2017-08-30 | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (es) |
| EP (2) | EP3741760A1 (es) |
| JP (1) | JP7194683B2 (es) |
| KR (1) | KR102594251B1 (es) |
| CN (2) | CN115181108A (es) |
| AR (1) | AR109467A1 (es) |
| AU (1) | AU2017351756B2 (es) |
| BR (2) | BR102016024814A2 (es) |
| CA (1) | CA3042040A1 (es) |
| CL (1) | CL2019001105A1 (es) |
| CO (1) | CO2019004756A2 (es) |
| DK (1) | DK3529234T3 (es) |
| EC (1) | ECSP19032963A (es) |
| ES (1) | ES2970546T3 (es) |
| FI (1) | FI3529234T3 (es) |
| MX (1) | MX2019004782A (es) |
| PE (1) | PE20191046A1 (es) |
| PT (1) | PT3529234T (es) |
| SG (2) | SG11201903113TA (es) |
| UY (1) | UY37334A (es) |
| WO (1) | WO2018076090A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019004685A (es) | 2016-10-24 | 2019-08-21 | Astrazeneca Ab | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer. |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| MY196317A (en) | 2017-01-30 | 2023-03-24 | Astrazeneca Ab | Estrogen Receptor Modulators |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| WO1995034304A1 (fr) * | 1994-06-10 | 1995-12-21 | Nauchno-Issledovatelsky Institut Farmakologii Rossiyskoi Akademii Meditsinskikh Nauk | Derives de 2-mercaptobenzimidazole pharmacologiquement actifs |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| IL129999A (en) | 1996-12-10 | 2004-06-20 | Bristol Myers Squibb Co | Melatonergic agents which are benzodioxole, benzopuran, dihydrobenzopuran and benzodioxane |
| US6214869B1 (en) | 1998-06-05 | 2001-04-10 | Bristol-Myers Squibb | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| US6211225B1 (en) | 1999-06-30 | 2001-04-03 | Bristol-Meyers Squibb | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| US7408067B2 (en) * | 2002-01-17 | 2008-08-05 | Merck + Co., Inc. | Aza-cyclic compounds as modulators of acetylcholine receptors |
| CN1922141A (zh) * | 2004-02-23 | 2007-02-28 | 大日本住友制药株式会社 | 新的杂环化合物 |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| CA2663189A1 (en) * | 2006-09-12 | 2008-03-20 | Pfizer Products Inc. | Benzimidazolone derivatives |
| WO2008051533A2 (en) * | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001037334A patent/UY37334A/es unknown
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es unknown
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 EP EP20185268.8A patent/EP3741760A1/en active Pending
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 BR BR112019008197A patent/BR112019008197A2/pt active Search and Examination
- 2017-10-23 MX MX2019004782A patent/MX2019004782A/es unknown
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en active Application Filing
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active IP Right Grant
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 CA CA3042040A patent/CA3042040A1/en active Pending
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
| CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
| DOP2018000184A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| AR107519A1 (es) | Compuestos de piperidina sustituido y su uso | |
| AR109467A1 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
| AR109348A1 (es) | Sulfonilureas y compuestos relacionados y sus usos | |
| AR101586A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| AR100251A1 (es) | Inhibidores de la dematilasa-1 especifica de lisina | |
| AR094309A1 (es) | Compuesto heterociclico fusionado y uso del mismo para el control de plagas | |
| AR061644A1 (es) | Derivados de benzofurano | |
| AR091710A1 (es) | Composiciones pesticidas y procesos relacionados con las mismas | |
| AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| CY1121626T1 (el) | Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου | |
| PE20161407A1 (es) | Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide | |
| AR090596A1 (es) | Formulaciones farmaceuticas que comprenden antagonistas de ccr3 | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| AR102731A1 (es) | Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor | |
| AR094935A1 (es) | Tosilato de n-hidroxi-4-{2-[3-(n,n-dimetilaminometil)benzofuran-2-ilcarbonil-amino]etoxi}benzamida (abexinostat) | |
| CO2017005416A2 (es) | Compuestos a base de fenilo sustituidos con porciones de aldehído | |
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| PH12019500589A1 (en) | Novel mesoionic insecticidal compound | |
| AR110240A1 (es) | Compuestos de diaminotriazina | |
| CO2017003830A2 (es) | Compuestos de piridina |